Login to Your Account



CV Therapeutics Starts Phase III For CVT-3146, Waits On Ranexa

By Kim Coghill


Thursday, October 30, 2003
CV Therapeutics Inc. initiated a pivotal Phase III trial for CVT-3146, a candidate for use as a pharmacologic stress agent in cardiac perfusion imaging studies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription